WO2004103317A3 - Transdermal buprenorphine dosage regimen for treatment of diarrhea - Google Patents

Transdermal buprenorphine dosage regimen for treatment of diarrhea Download PDF

Info

Publication number
WO2004103317A3
WO2004103317A3 PCT/US2004/009335 US2004009335W WO2004103317A3 WO 2004103317 A3 WO2004103317 A3 WO 2004103317A3 US 2004009335 W US2004009335 W US 2004009335W WO 2004103317 A3 WO2004103317 A3 WO 2004103317A3
Authority
WO
WIPO (PCT)
Prior art keywords
diarrhea
dosage regimen
symptoms
treatment
transdermal buprenorphine
Prior art date
Application number
PCT/US2004/009335
Other languages
French (fr)
Other versions
WO2004103317A2 (en
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Bruce E Reidenberg
Daniel A Spyker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Bruce E Reidenberg, Daniel A Spyker filed Critical Euro Celtique Sa
Publication of WO2004103317A2 publication Critical patent/WO2004103317A2/en
Publication of WO2004103317A3 publication Critical patent/WO2004103317A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Abstract

A buprenorphine transdermal dosage regimen is provided that reduces symptoms such as pain and/or diarrhea are effectively reduced in patients suffering from one or more gastrointestinal conditions. The dosage regimen reduces the severity of breakthrough symptoms in a patient treated for symptoms of diarrhea. The gastrointestinal conditions include irritable bowel syndrome (IBS), short gut syndrome, microscopic colitis, and diarrhea associated with VIP-secreting carcinoids.
PCT/US2004/009335 2003-05-15 2004-03-26 Transdermal buprenorphine dosage regimen for treatment of diarrhea WO2004103317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47148003P 2003-05-15 2003-05-15
US60/471,480 2003-05-15

Publications (2)

Publication Number Publication Date
WO2004103317A2 WO2004103317A2 (en) 2004-12-02
WO2004103317A3 true WO2004103317A3 (en) 2005-03-10

Family

ID=33476852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009335 WO2004103317A2 (en) 2003-05-15 2004-03-26 Transdermal buprenorphine dosage regimen for treatment of diarrhea

Country Status (1)

Country Link
WO (1) WO2004103317A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41489E1 (en) 1997-02-24 2010-08-10 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
JP5054893B2 (en) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． Transdermal buprenorphine for analgesia
NZ545505A (en) 2003-07-25 2010-02-26 Euro Celtique Sa Transdermal administration of buprenorphine for treatment of dependence withdrawal
PT3137081T (en) * 2014-04-28 2018-02-08 Orphomed Inc Buprenorphine dimer and its use in treatment of gastrointestinal disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6306876B1 (en) * 1999-12-22 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6306876B1 (en) * 1999-12-22 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41489E1 (en) 1997-02-24 2010-08-10 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine

Also Published As

Publication number Publication date
WO2004103317A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
MXPA05010819A (en) The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome.
WO2007130892A3 (en) Method for treatment of constipation-predominant irritable bowel syndrome
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2006031980A3 (en) Treatment for cancer-related fatigue
EP1377380A4 (en) Apparatus for treating waste, particularly medical waste, to facilitate its disposition
WO2003090695A3 (en) TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
IL160754A0 (en) Dosage form, device and methods of treatment
WO2004043223A3 (en) Compositions and methods for the diagnosis and treatment of sepsis
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
DK1663257T3 (en) Use of laxatives to treat colon irritable
WO2004103317A3 (en) Transdermal buprenorphine dosage regimen for treatment of diarrhea
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP2088469A4 (en) Solution for treatment of resist substrate after development processing, and method for treatment of resist substrate using the same
WO2008067351A3 (en) Method of diagnosing and treating glioma
WO2009002652A3 (en) Use of surfactants for treating mycobacterial infections
WO2008063853A3 (en) Cancer treatment method
WO2007118077A3 (en) Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis
WO2002036124A3 (en) Treatment and method using loratadine and montelukast
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
PL1830833T3 (en) Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
TW200500585A (en) Device and method for heat treatment
GB2368524B (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase